Literature DB >> 7598687

Modified amyloid beta protein ending at 42 or 40 with different solubility accumulates in the brain of Alzheimer's disease.

Y Harigaya1, M Shoji, T Kawarabayashi, M Kanai, T Nakamura, T Iizuka, Y Igeta, T C Saido, N Sahara, H Mori.   

Abstract

Serial extraction study of Alzheimer's disease (AD) and control brains revealed 4, 3.7 and 3 kD amyloid beta protein (A beta) species accumulated in AD brains. In the fractions extracted with TBS, 10% SDS and formic acid, considerable amounts of A beta species were recovered in SDS fractions besides TBS and formic acid fractions. Immunoblotting with several site-specific antibodies confirmed not only the presence of 4 kD A beta starting at the first amino acid of A beta but also 2 smaller A beta species with modification of their amino-termini in the highly resolutional Tris/Tricine gel system. A beta solubility using these solvents was associated with both modification of the amino-terminus and length of carboxyl-terminus of A beta. Especially, a large amount of modified A beta was found to be accumulated as forms with different solubility in AD brains.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7598687     DOI: 10.1006/bbrc.1995.1912

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  7 in total

1.  Cerebral amyloid angiopathy: amyloid beta accumulates in putative interstitial fluid drainage pathways in Alzheimer's disease.

Authors:  R O Weller; A Massey; T A Newman; M Hutchings; Y M Kuo; A E Roher
Journal:  Am J Pathol       Date:  1998-09       Impact factor: 4.307

2.  Neuropathology and amyloid-β spectrum in a bapineuzumab immunotherapy recipient.

Authors:  Alex E Roher; Chera L Maarouf; Ian D Daugs; Tyler A Kokjohn; Jesse M Hunter; Marwan N Sabbagh; Thomas G Beach
Journal:  J Alzheimers Dis       Date:  2011       Impact factor: 4.472

3.  Effect of apolipoprotein E allele epsilon4 on the initial phase of amyloid beta-protein accumulation in the human brain.

Authors:  M Morishima-Kawashima; N Oshima; H Ogata; H Yamaguchi; M Yoshimura; S Sugihara; Y Ihara
Journal:  Am J Pathol       Date:  2000-12       Impact factor: 4.307

Review 4.  APP/Aβ structural diversity and Alzheimer's disease pathogenesis.

Authors:  Alex E Roher; Tyler A Kokjohn; Steven G Clarke; Michael R Sierks; Chera L Maarouf; Geidy E Serrano; Marwan S Sabbagh; Thomas G Beach
Journal:  Neurochem Int       Date:  2017-08-12       Impact factor: 3.921

5.  An anti-pyroglutamate-3 Aβ vaccine reduces plaques and improves cognition in APPswe/PS1ΔE9 mice.

Authors:  Jeffrey L Frost; Bin Liu; Jens-Ulrich Rahfeld; Martin Kleinschmidt; Brian O'Nuallain; Kevin X Le; Inge Lues; Barbara J Caldarone; Stephan Schilling; Hans-Ulrich Demuth; Cynthia A Lemere
Journal:  Neurobiol Aging       Date:  2015-08-31       Impact factor: 4.673

6.  Detection of a novel intraneuronal pool of insoluble amyloid beta protein that accumulates with time in culture.

Authors:  D M Skovronsky; R W Doms; V M Lee
Journal:  J Cell Biol       Date:  1998-05-18       Impact factor: 10.539

7.  Oral Immunization with Soybean Storage Protein Containing Amyloid-β 4-10 Prevents Spatial Learning Decline.

Authors:  Takeshi Kawarabayashi; Teruhiko Terakawa; Atsushi Takahashi; Hisakazu Hasegawa; Sakiko Narita; Kaoru Sato; Takumi Nakamura; Yusuke Seino; Mie Hirohata; Nobue Baba; Tetsuya Ueda; Yasuo Harigaya; Fuyuki Kametani; Nobuyuki Maruyama; Masao Ishimoto; Peter St George-Hyslop; Mikio Shoji
Journal:  J Alzheimers Dis       Date:  2019       Impact factor: 4.472

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.